Literature DB >> 9700207

5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease.

C Holmes1, M J Arranz, J F Powell, D A Collier, S Lovestone.   

Abstract

The psychopathology of Alzheimer's disease (AD) is varied and includes both behavioural and psychological symptoms. Behavioural and psychological symptoms are common and contribute to the difficulties experienced by carers. However, the mechanism whereby these symptoms occur in some individuals with AD is not understood. We hypothesized that common genetic polymorphisms in neurotransmitter systems are risk factors for these symptoms in the course of AD. A total of 211 subjects from a population-based prospective study of psychopathology within late-onset AD were genotyped for the 5-HT2A receptor polymorphism 102-T/C and the 5-HT2C receptor polymorphism Cys23Ser. Associations were found between the presence of the C102 allele and the presence of visual (Fisher's exact test, one-tailed, P = 0.003) and auditory hallucinations (Fisher's exact test, one-tailed, P = 0.004) and between the presence of the Ser23 allele and visual hallucinations (chi2 = 7.5, df = 1, P = 0.006) (P = 0.03, 0.04 and 0.06, respectively, after Bonferroni correction). In addition, there was an association between the Cys23Ser polymorphism and hyperphagia (chi2 = 6.7, df = 2, P = 0.03) (P = 0.3 after Bonferroni correction). We conclude that common 5-HT2A and 5-HT2C genetic polymorphisms previously showing only weak associations with psychotic illness are associated with psychotic symptoms in AD but are clinically silent until the onset of the neurodegenerative process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700207     DOI: 10.1093/hmg/7.9.1507

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  31 in total

Review 1.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Genetics of psychosis of Alzheimer disease.

Authors:  Chintan Shah; Mary Ann A DeMichele-Sweet; Robert A Sweet
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-01-12       Impact factor: 3.568

3.  Estimating RNA editing efficiency of five editing sites in the serotonin 2C receptor by pyrosequencing.

Authors:  Kazuya Iwamoto; Miki Bundo; Tadafumi Kato
Journal:  RNA       Date:  2005-10       Impact factor: 4.942

4.  Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease.

Authors:  Robyn Carson; David Craig; Dominic Hart; Stephen Todd; Bernadette McGuinness; Janet A Johnston; Francis A O'Neill; Craig W Ritchie; A Peter Passmore
Journal:  Neuromolecular Med       Date:  2008-08-12       Impact factor: 3.843

5.  ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility.

Authors:  M Kołaczkowski; P Mierzejewski; P Bieńkowski; A Wesołowska; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

6.  Prominent neuroleptic sensitivity in a case of early-onset Alzheimer disease due to presenilin-1 G206A mutation.

Authors:  Steven P Cercy; Martin J Sadowski; Thomas Wisniewski
Journal:  Cogn Behav Neurol       Date:  2008-09       Impact factor: 1.600

7.  Serotonergic regulation of excitability of principal cells of the dorsal cochlear nucleus.

Authors:  Zheng-Quan Tang; Laurence O Trussell
Journal:  J Neurosci       Date:  2015-03-18       Impact factor: 6.167

8.  Delusions and hallucinations are associated with worse outcome in Alzheimer disease.

Authors:  Nikolaos Scarmeas; Jason Brandt; Marilyn Albert; Georgios Hadjigeorgiou; Alexandros Papadimitriou; Bruno Dubois; Maria Sarazin; Davangere Devanand; Lawrence Honig; Karen Marder; Karen Bell; Domonick Wegesin; Deborah Blacker; Yaakov Stern
Journal:  Arch Neurol       Date:  2005-10

9.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

10.  Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions.

Authors:  Josef Marksteiner; Reinhold Schmidt
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.